Bimatoprost slow-release for ocular hypertension or open-angle glaucoma

Bimatoprost slow-release (implant) is currently in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are unsuitable for topical IOP-lowering medications. OHT occurs when the IOP of the eye is raised and can cause glaucoma if untreated. Although OHT is a big risk factor for OAG, OAG can be caused by a number of other risk factors including age, comorbidities and family history. OAG is the most common form of glaucoma, and it is caused by fluid build-up in the eye. If untreated, it can lead to vision loss. Treatment of OHT and/or OAG are typically topical medicines and/or selective laser trabeculoplasty (SLT). However, the main issue with topical medicines, although effective, is poor treatment adherence.